Loading
CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer and 4 more.
Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest. Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Also involved in p53-independent DNA damage-induced G2 arrest mediated by CREB3L1 in astrocytes and osteoblasts.
CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Fluorouracil. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.76, literature 1.00, genetic association 0.62, somatic mutation 0.80, animal model 0.53). IntOGen calls it a driver in 9 cohorts (2 activating, 7 loss-of-function), covering Bladder Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Hepatocellular Carcinoma.
In plain words · CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer and 4 more.
CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer and 4 more.
Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest. Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage.
No product in this corpus aims at CDKN1A yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CDKN1A: RNA low tissue specificity; blood lineage group enriched (B-cells 21 nTPM, dendritic cells 22 nTPM, monocytes 75 nTPM); high antibody staining in 4 normal tissues; highest cancer staining cervical cancer (7 of 11 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer, Renal cell carcinoma, Breast cancer (all types), Childhood cancers (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (urinary bladder cancer). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P38936; CIViC gene CDKN1A; IntOGen CDKN1A; Human Protein Atlas CDKN1A tissue; Open Targets ENSG00000124762 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Harper J.W. et al, Cell, 1993, "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases". Source.
Sources: HGNC HGNC:1784 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P38936 (protein name, function text, keywords and locations (REST API)); CIViC gene CDKN1A (4 evidence items, 0 assertions, 4 variants; diseases: Retinoblastoma, Colorectal Cancer (GraphQL API, CC0)); Open Targets ENSG00000124762 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: urinary bladder cancer 0.64, breast cancer 0.51 (GraphQL API, CC0)); IntOGen CDKN1A (driver in 9 cohorts (Act 2, LoF 7); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest. Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Also involved in p53-independent DNA damage-induced G2 arrest mediated by CREB3L1 in astrocytes and osteoblasts. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localisation and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: group enriched (B-cells 21 nTPM, dendritic cells 22 nTPM, monocytes 75 nTPM).
Medium: Adipose tissue, Adrenal gland, Appendix, Bronchus, Colon, Duodenum, Endometrium, Epididymis.
Medium only: carcinoid, glioma, head and neck cancer, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CDKN1A" OR ABSTRACT:"CDKN1A" OR TITLE:"cyclin dependent kinase inhibitor 1A" OR ABSTRACT:"cyclin dependent kinase inhibitor 1A" OR TITLE:"Cyclin-dependent kinase inhibitor 1" OR ABSTRACT:"Cyclin-dependent kinase inhibitor 1" OR TITLE:"P21" OR ABSTRACT:"P21" OR TITLE:"CIP1" OR ABSTRACT:"CIP1" OR TITLE:"WAF1" OR ABSTRACT:"WAF1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN1A, not a curated reading list.
Shares The p53 network (guardian of the genome), CIViC, Breast cancer (all types), Open Targets Platform.
Shares Chromophobe renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares The cell-cycle engine (cyclins & CDKs), CIViC, IntOGen, Breast cancer (all types).
Shares Chromophobe renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares The cell-cycle engine (cyclins & CDKs), CIViC, IntOGen, Open Targets Platform.
Shares The p53 network (guardian of the genome), The cell-cycle engine (cyclins & CDKs), p53 / RB / cell-cycle checkpoint.
Shares The cell-cycle engine (cyclins & CDKs), CIViC, Open Targets Platform.
Shares Retinoblastoma, Renal cell carcinoma, Hepatocellular carcinoma.